Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.70 |
| ▸ | PLK1 | P53350 | 4/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241620 | 0.91 | KDR (0.70) | KDRPLK1PTK2IGF1RJAK2 | |
| SCHEMBL7230278 | 0.89 | KDR (0.67) | KDRPLK1PTK2IGF1RJAK2 | |
| SCHEMBL7234789 | 0.81 | KDR (0.64) | KDRPLK1PTK2INSRAURKB | |
| SCHEMBL7232394 | 0.81 | KDR (0.64) | KDRPLK1PTK2IGF1RJAK2 | |
| SCHEMBL7239285 | 0.81 | KDR (0.63) | KDRPLK1PTK2IGF1RPDGFRB | |
| SCHEMBL7237382 | 0.81 | KDR (0.63) | KDRPLK1PTK2INSRAURKB | |
| Hydrochloric Acid SCHEMBL7518134 | 0.80 | KDR (0.62) | KDRPLK1PTK2IGF1RPDGFRB | |
| SCHEMBL7235444 | 0.80 | IKBKB (0.67) | KDRPLK1PTK2AURKBIGF1R | |
| Hydrochloric Acid SCHEMBL7516453 | 0.79 | IKBKB (0.66) | KDRPLK1PTK2AURKBIGF1R | |
| SCHEMBL7238442 | 0.79 | KDR (0.60) | KDRPLK1PTK2AURKBPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057329-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |